AstraZeneca’ COVID-19 vaccine trial in the United States is expected to resume as early as this week after the FDA completed its review of a serious illness, Julie Steenhuysen and Marisa Taylor of Reuters report, citing four sources. The trial has been on hold since September 6 after a participant in the company’s U.K. trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis, Reuters notes.